Clinical Drug Experience Knowledgebase

asparaginase (elspar) (2 trials)

cladribine (leustatin) (2 trials)

cyclophosphamide (cytoxan) (13 trials)

cytarabine (cytosar-u) (8 trials)

daunorubicin (cerubidine) (7 trials)

doxorubicin (Doxil) (9 trials)

etoposide (vepesid) (8 trials)

fludarabine (fludara) (3 trials)

idarubicin (idamycin) (2 trials)

ifosfamide (ifex) (6 trials)

mercaptopurine (purinethol) (5 trials)

mitoxantrone (novantrone) (1 trial)

naltrexone (revia) (4 trials)

prednisone (meticorten) (10 trials)

sargramostim (leukine) (2 trials)

stem cells (2 trials)

teniposide (vumon) (2 trials)

tioguanine (Lanvis) (6 trials)

urea (3 trials)

vinblastine (velban) (2 trials)

vincristine (oncovin) (11 trials)

aldoxorubicin (1 trial)

allogeneic stem cells (1 trial)

autologous mononuclear stem cell (1 trial)

blinatumomab (blincyto) (1 trial)

bortezomib (velcade) (1 trial)

capecitabine (xeloda) (1 trial)

cisplatin (platinol) (3 trials)

cycloheximide (1 trial)

dacarbazine (dtic-dome) (3 trials)

defibrotide (defitelio) (1 trial)

dexamethasone (3 trials)

docetaxel (taxotere) (2 trials)

erwinia asparaginase (Erwinaze) (1 trial)

fludeoxyglucose f-18 (1 trial)

fluorouracil (efudex) (4 trials)

gemcitabine (gemzar) (1 trial)

leucovorin (3 trials)

methotrexate (3 trials)

oxaliplatin (eloxatin) (3 trials)

paclitaxel (taxol) (1 trial)

pegaspargase (oncaspar) (3 trials)

prednisolone (hydeltra) (3 trials)

procarbazine (matulane) (2 trials)

rituximab (rituxan) (3 trials)

somatostatin (1 trial)

vindesine (Eldisine) (4 trials)

alectinib (alecensa) (1 trial)

aminolevulinic acid (levulan) (1 trial)

apg101 (1 trial)

atezolizumab (Tecentriq) (2 trials)

bleomycin (blenoxane) (1 trial)

carboplatin (paraplatin) (1 trial)

donor-derived ebv-specific cytotoxic t-cells transduced with the retroviral vector sfgalpha-cd19-cd3zeta (1 trial)

idasanutlin (1 trial)

interferon alpha-2b (Intron-A) (1 trial)

irradiated donor lymphocyte (1 trial)

l-epigallocatechin (1 trial)

methadone (methadose) (1 trial)

palbociclib (ibrance) (1 trial)

temsirolimus (torisel) (1 trial)

topotecan (hycamtin) (1 trial)

vismodegib (erivedge) (1 trial)

h3k27m peptide vaccine (1 trial)

imiquimod (aldara) (1 trial)

truncated tissue factor (1 trial)

125-iodine (1 trial)

i-124 (1 trial)